Marietta Iacucci
Overview
Explore the profile of Marietta Iacucci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
173
Citations
2924
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buda A, Pessarelli T, Aldinio G, De Bona M, Iacucci M, Tontini G
Dig Liver Dis
. 2025 Mar;
PMID: 40074573
Mucosal healing is the mainstream goal of modern treat-to-target strategy as it is associated with a significantly more favorable disease course in IBD patients with either ulcerative colitis or Crohn's...
2.
Iacucci M, Santacroce G, Maeda Y, Ghosh S
Gastroenterology
. 2025 Mar;
PMID: 40074186
Inflammatory bowel disease (IBD) is marked by significant clinical heterogeneity, posing challenges for accurate diagnosis and personalized treatment strategies. Conventional approaches, such as endoscopy and histology, often fail to adequately...
3.
Iacucci M, Maeda Y, Santacroce G, Ghosh S
Nat Rev Gastroenterol Hepatol
. 2025 Mar;
PMID: 40033062
No abstract available.
4.
Acharjee A, Shivaji U, Santacroce G, Akiror S, Jeffery L, Varnai C, et al.
Inflamm Bowel Dis
. 2025 Feb;
PMID: 39977234
Background: Fibrosis is a common complication in Crohn's disease (CD), often leading to intestinal strictures. This study aims to explore the transcriptomic signature of fibrostenotic ileal CD for a comprehensive...
5.
Maeda Y, Ditonno I, Puga-Tejada M, Zammarchi I, Santacroce G, Ghosh S, et al.
eGastroenterology
. 2025 Feb;
2(3):e100090.
PMID: 39944363
Endoscopic remission is the primary long-term therapeutic goal in inflammatory bowel disease (IBD). The assessment of this therapeutic target typically relies on white light endoscopy (WLE) combined with histological sampling....
6.
Vieujean S, Jairath V, Peyrin-Biroulet L, Dubinsky M, Iacucci M, Magro F, et al.
Nat Rev Gastroenterol Hepatol
. 2025 Feb;
PMID: 39930068
No abstract available.
7.
Vieujean S, Jairath V, Peyrin-Biroulet L, Dubinsky M, Iacucci M, Magro F, et al.
Nat Rev Gastroenterol Hepatol
. 2025 Jan;
PMID: 39891014
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a group of chronic, immune-mediated disorders of the gastrointestinal tract that present substantial clinical challenges owing to their complex...
8.
Kuroki T, Maeda Y, Kudo S, Ogata N, Takabayashi K, Takenaka K, et al.
J Crohns Colitis
. 2025 Jan;
19(1).
PMID: 39888722
Background And Aims: The long-term treat-to-target (T2T) approach in ulcerative colitis (UC) aims for endoscopic remission, but variability among endoscopists and a lack of precision in relapse prediction both limit...
9.
Puga-Tejada M, Majumder S, Maeda Y, Zammarchi I, Ditonno I, Santacroce G, et al.
J Crohns Colitis
. 2025 Jan;
19(1.
PMID: 39742395
Background And Aims: Achieving histological remission is a desirable emerging treatment target in ulcerative colitis (UC), yet its assessment is challenging due to high inter- and intraobserver variability, reliance on...
10.
Sinopoulou V, Nigam G, Gordon M, Ganeshan M, Tokonyai M, Dolwani S, et al.
Clin Gastroenterol Hepatol
. 2024 Dec;
PMID: 39675405
Background & Aims: Long-standing inflammatory bowel disease (IBD) increases the risk of colonic neoplasia, necessitating effective screening strategies. This network meta-analysis compared the efficacy and safety between different endoscopic modalities...